Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.
Journal
Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
medline:
29
3
2023
pubmed:
14
12
2022
entrez:
13
12
2022
Statut:
ppublish
Résumé
Background The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific antigen (PSA) level and no previous biopsy. Purpose To assess how Gleason grade, maximum cancer core length (MCCL), inflammation, prostatic intraepithelial neoplasia (PIN), or atypical small acinar proliferation within a Barzell zone affects the odds of MRI visibility. Materials and Methods In this secondary analysis of the Prostate MRI Imaging Study (PROMIS; May 2012 to November 2015), consecutive participants who underwent multiparametric MRI followed by a combined biopsy, including 5-mm transperineal mapping (TPM), were evaluated. TPM pathologic findings were reported at the whole-prostate level and for each of 20 Barzell zones per prostate. An expert panel blinded to the pathologic findings reviewed MRI scans and declared which Barzell areas spanned Likert score 3-5 lesions. The relationship of Gleason grade and MCCL to zonal MRI outcome (visible vs nonvisible) was assessed using generalized linear mixed-effects models with random intercepts for individual participants. Inflammation, PIN, and atypical small acinar proliferation were similarly assessed in men who had negative TPM results. Results Overall, 161 men (median age, 62 years [IQR, 11 years]) were evaluated and 3179 Barzell zones were assigned MRI status. Compared with benign areas, the odds of MRI visibility were higher when a zone contained cancer with a Gleason score of 3+4 (odds ratio [OR], 3.1; 95% CI: 1.9, 4.9;
Identifiants
pubmed: 36511804
doi: 10.1148/radiol.220762
pmc: PMC7614676
mid: EMS174630
doi:
Banques de données
ClinicalTrials.gov
['NCT01292291']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e220762Subventions
Organisme : Medical Research Council
ID : MR/S005897/1
Pays : United Kingdom
Organisme : Department of Health
ID : 09/22/67
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/20
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/28
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R014043/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S00680X/1
Pays : United Kingdom
Organisme : Prostate Cancer UK
ID : PG10-17
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00004/02
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Références
Eur Urol. 2020 Aug;78(2):163-170
pubmed: 32370911
Am J Surg Pathol. 2020 Aug;44(8):e87-e99
pubmed: 32459716
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
BJU Int. 2012 Sep;110(6):812-20
pubmed: 22394583
Br J Cancer. 2017 Apr 25;116(9):1159-1165
pubmed: 28350785
Magn Reson Imaging. 2020 Apr;67:50-58
pubmed: 31899283
Prostate. 2022 Feb;82(3):388-396
pubmed: 34914121
Eur Urol. 2021 Jan;79(1):20-29
pubmed: 33051065
Eur Urol. 2021 Jan;79(1):30-32
pubmed: 33162247
Radiology. 2015 Dec;277(3):751-62
pubmed: 26110669
Mod Pathol. 2019 Oct;32(10):1536-1543
pubmed: 31175330
Clin Oncol (R Coll Radiol). 2016 Sep;28(9):568-76
pubmed: 27318423
Nat Rev Urol. 2018 Jan;15(1):55-66
pubmed: 28858331
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1028-1031
pubmed: 33958731
J Med Imaging Radiat Oncol. 2017 Apr;61(2):212-215
pubmed: 27987276
J Urol. 2011 Aug;186(2):458-64
pubmed: 21679984
Hum Pathol. 2019 Jan;83:159-165
pubmed: 30179687
In Vivo. 1994 May-Jun;8(3):439-43
pubmed: 7803731
Urol Oncol. 2020 Jul;38(7):636.e7-636.e12
pubmed: 32113858
Insights Imaging. 2018 Feb;9(1):87-101
pubmed: 29063480
Eur Urol. 2020 Sep;78(3):443-451
pubmed: 32360049
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):258-63
pubmed: 27401032
Investig Clin Urol. 2019 Sep;60(5):388-395
pubmed: 31501802